Plus Therapeutics Stock Jumps After FDA Orphan Drug Win for Kids’ Rare Brain Tumors Plus Therapeutics’ REYOBIQ gets FDA orphan drug status for rare kids’ brain tumors. Credit: Plus Therapeutics Subscribe now Already have an account? Sign in.
